Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
本文は利用できません。元の情報源をご確認ください。
Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.